Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma

Annals of Surgical Oncology

Volumn 21, Issue 7, 2014, Pages 2259-2266

  Acuna, Sergio A ^a   Ottolino Perry, Kathryn ^a,b   Çako, Besmira ^a   Tang, Nan ^a   Angarita, Fernando A ^a,b   McCart, J Andrea ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CRYSTAL VIOLET; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CELL VIABILITY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; EXPERIMENTAL STUDY; FEMALE; FOLLOW UP; LONG TERM SURVIVAL; MESOTHELIOMA CELL LINE; MICROSCOPY; MOUSE; MURINE MODEL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PERITONEUM CANCER; PERITONEUM MESOTHELIOMA; SURVIVAL; VACCINIA VIRUS; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CBA MOUSE; CELL PROLIFERATION; ENZYME IMMUNOASSAY; HUMAN; LUNG NEOPLASMS; MESOTHELIOMA; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERITONEAL NEOPLASMS; PHYSIOLOGY; SCID MOUSE; SURVIVAL RATE; TUMOR CELL CULTURE; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; APOPTOSIS; CELL PROLIFERATION; COMBINED MODALITY THERAPY; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; MICE, SCID; ONCOLYTIC VIROTHERAPY; PERITONEAL NEOPLASMS; SURVIVAL RATE; TUMOR CELLS, CULTURED; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 84902127520     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3651-4     Document Type: Article

References (33)

1. Mack TM. Sarcomas and other malignancies of soft tissue, retroperitoneum, peritoneum, pleura, heart, mediastinum, and spleen. Cancer. 1995;75(1 Suppl):211-44.
2. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366(9483):397-408.
3. Manzini Vde P, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010;21(2):348-53.
4. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237-42.
5. Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma: an update on treatment. Cancer Treat Rev. 2012;38(6):605-12.
6. Sugarbaker PH. Managing the peritoneal surface component of gastrointestinal cancer. Part 2: perioperative intraperitoneal chemotherapy. Oncology (Williston Park). 2004;18(2):207-19; discussion 220-2, 227-8, 230.
7. Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32(6):686-91.
8. Sugarbaker PH. Evolution of cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis: are there treatment alternatives? Am J Surg. 2011;201(2):157-9.
9. Adusumilli PS, Stiles BM, Chan MK, et al. Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. J Gene Med. 2006;8(5):603-15.
10. Zhu ZB, Makhija SK, Lu B, et al. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses. J Thorac Oncol. 2006;1(7):701-11.
11. Kubo S, Kawasaki Y, Yamaoka N, et al. Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus. J Gene Med. 2010;12(8):681-92.
12. Willmon CL, Saloura V, Fridlender ZG, et al. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res. 2009;69(19):7713-20.
13. Saloura V, Wang LC, Fridlender ZG, et al. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther. 2010;21(1):51-64.
14. Silberhumer GR, Brader P, Wong J, et al. Genetically engineered oncolytic newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther. 2010;9(10):2761-9.
15. Gauvrit A, Brandler S, Sapede-Peroz C, Boisgerault N, Tangy F, Gregoire M. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res. 2008;68(12):4882-92.
16. Kelly KJ, Woo Y, Brader P, et al. Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma. Hum Gene Ther. 2008;19(8):774-82.
17. Zhang Q, Yu YA, Wang E, et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 2007;67(20):10038-46.
18. Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477(7362):99-102.
19. Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008;9(6):533-42.
20. Hwang TH, Moon A, Burke J, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther. 2011;19(10):1913-22.
21. McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001;61(24):8751-7.
22. Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Establishment of a murine model of malignant mesothelioma. Int J Cancer. 1992;52(6):881-6.
23. McCart JA, Mehta N, Scollard D, et al. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther. 2004;10(3):553-61.
24. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon's role. Langenbecks Arch Surg. 1999;384(6):576-87.
25. Jansen M, Treutner KH, Jansen PL, et al. Inhibition of gastric cancer cell adhesion in nude mice by inraperitoneal phospholipids. World J Surg. 2005;29(6):708-14.
26. Jarnagin WR, Zager JS, Klimstra D, et al. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Cancer Gene Ther. 2003;10(3):215-23.
27. Ebright MI, Zager JS, Malhotra S, et al. Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. J Thorac Cardiovasc Surg. 2002;124(1):123-9.
28. Sugarbaker PH. Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: The Washington Cancer Institute approach. Expert Opin Pharmacother. 2009;10(12):1965-77.
29. Bertino P, Panigada M, Soprana E, et al. Fowlpox-based survivin vaccination for malignant mesothelioma therapy. Int J Cancer. 2013;133(3):612-23.
30. Ho M, Feng M, Fisher RJ, Rader C, Pastan I. A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer. 2011;128(9):2020-30.
31. Feng Y, Xiao X, Zhu Z, et al. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther. 2009;8(5):1113-8.
32. Bridle BW, Stephenson KB, Boudreau JE, et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther. 2010;18(8):1430-9.
33. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther. 2010;18(2):251-63.